10-K: Dror Ortho-Design Secures FDA Clearance for ZSmile Platform

Dror Ortho-Design, a development-stage company, announced FDA 510(k) clearance for its ZSmile orthodontic platform, despite ongoing operating losses and significant liquidity challenges.

Summary

• Dror Ortho-Design, Inc. (formerly Novint Technologies, Inc.) is a development-stage company focused on an AI-based orthodontic alignment platform called ZSmile.
• The ZSmile Platform, a Class II medical device, received 510(k) clearance from the FDA for commercialization in the U.S. in February 2026, building on its first-generation Aerodentis System which received FDA clearance in April 2020.
• The company is not currently generating revenues and incurred net losses of $2.5 million in 2025 and $5.8 million in 2024.
• As of December 31, 2025, the company had cash of approximately $228,000, a working capital deficit of $2.7 million, and an accumulated deficit of $22 million.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient liquidity.
• Dror Ortho-Design plans to spend approximately $1 million over the next 12 months on software and hardware development, regulatory approvals, and IP protection.
• The company raised $1.75 million in bridge loans from existing investors during 2025 and an additional $200,000 in February 2026, with these debentures convertible into common stock upon a public offering.
• The ZSmile Platform utilizes a smartphone application, an AI-based cloud service, and a smart aligner system that uses pulsating air for nighttime tooth movement, requiring only one aligner per patient.
• The global clear aligners market was estimated at $8.3 billion in 2025 and is projected to reach $56.8 billion by 2033, with Dror Ortho-Design targeting a potential addressable market of $17 billion.
• The company's business model aims to expand the target distribution channel to general dentists, who outnumber orthodontists by approximately 15 to 1 in the U.S.
• The company has three issued U.S. patents (expiring 2030, 2040, 2040) and four pending U.S. patents covering its technology.
• A material weakness in internal control over financial reporting was identified as of December 31, 2025, due to limited accounting personnel and the absence of a Chief Financial Officer.
• The company's operations are based in Israel, exposing it to economic, political, geopolitical, and military risks, including recent conflicts with Hamas, Hezbollah, and Iran.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant financial distress, including recurring losses, a going concern warning, and material weaknesses in internal controls, despite the positive FDA clearance for its core product.

Positives

• The ZSmile Platform, a next-generation orthodontic solution, received 510(k) clearance from the FDA in February 2026, enabling commercialization in the U.S.
• The company's technology, including the ZSmile Platform, has multiple issued U.S. patents (expiring 2030, 2040, 2040) and pending applications, protecting critical aspects like pulsating air tooth movement and 3D printing.
• The ZSmile Platform's design, requiring only one smart aligner per patient, allows for cost-effective 3D printing production, a superior method for precision and customizability not feasible for traditional multi-aligner solutions.
• The company's business model targets both orthodontists and general dentists, significantly expanding its addressable practitioner market (general dentists outnumber orthodontists 15 to 1 in the U.S.).
• The ZSmile AI Cloud's machine learning algorithm is designed to improve 3D image accuracy from smartphone videos, potentially replacing intraoral scans for certain cases and increasing efficiency in the dental industry.
• The company successfully passed its ISO/MDSAP certification process and renewed its annual inspection in April 2023, demonstrating compliance with quality and safety standards for medical devices.
• The company secured $1.75 million in bridge loans during 2025 and an additional $200,000 in February 2026, providing some liquidity for ongoing operations.

Negatives

• The company is in the development stage, is not generating revenues, and has incurred significant net operating losses of $2.5 million in 2025 and $5.8 million in 2024.
• As of December 31, 2025, the company had a cash balance of only $228,000 and a working capital deficit of approximately $2.7 million, indicating insufficient liquidity to fund future operations.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting was identified as of December 31, 2025, due to limited accounting personnel and the lack of a Chief Financial Officer, posing risks to financial reporting accuracy and compliance.
• Research and development expenses decreased by 47% in 2025 to $815,902, primarily due to decreased outsourced consulting activities resulting from limited funding, which could impact future product enhancements.
• The company's common stock is not listed on any major stock exchange, trades on the OTC Pink Market, and is subject to penny stock rules, limiting liquidity and potentially leading to wide price fluctuations.
• The management team lacks U.S. public company experience, which may put the company at a competitive disadvantage and impair its ability to comply with U.S. securities laws and GAAP requirements.

Risks

• Operations and financial performance depend on global and regional economic conditions, including inflation, currency exchange rate fluctuations, and recessions, which could materially affect the business.
• The company is in the development stage, is not generating revenues, and has no operating history in the manufacturing and distribution of orthodontic medical devices or platforms for consumer use.
• Products and technologies may not be accepted by intended commercial consumers, which could harm future financial performance.
• Continued operating losses are expected, and future profitability cannot be certain.
• Net revenues will depend primarily on the ZSmile Platform, and any decline in sales or average selling price may adversely affect net revenues, gross margin, and net income.
• The company will face competition from large internationally established aligner companies whose products have been widely accepted.
• Growth and future success depend on the ability to enhance the Platform or to develop, obtain regulatory clearance for, successfully introduce, and achieve market acceptance of new products and services.
• Subject to operating risks, including excess or constrained capacity and operational inefficiencies, which could adversely affect results of operations.
• Issues with product development or enhancements, IT system integration, implementation, updates, and upgrades could disrupt operations and have a material impact on business and operating results.
• Complying with regulations enforced by FDA and other regulatory authorities is expensive and time-consuming, and failure to comply could result in substantial penalties.
• May not receive necessary authorizations to market future new products, and any failure to timely do so may adversely affect the ability to grow the business.
• Certain modifications to products may require new 510(k) clearance or other marketing authorizations.
• Ongoing changes in healthcare regulation could negatively affect revenues, business, and financial condition.
• Subject to certain federal, state, and foreign fraud and abuse laws, health information privacy and security laws, and transparency laws, which, if violated, could subject the company to substantial penalties.
• Success depends in part on proprietary technology, and if unable to successfully enforce intellectual property rights, competitive position may be harmed.
• The relative lack of U.S. public company experience of the management team may put the company at a competitive disadvantage.
• Common stock is not listed on any stock exchange and there is a limited market for shares, which could be subject to wide fluctuations.
• Operations are conducted in Israel, and conditions in Israel, including recent attacks by Hamas and other terrorist organizations and Israel's war against them, may affect operations, supply chains, and ability to raise capital.
• Business could be impacted by major public health issues, including future pandemics.
• Business could be impacted by political events, trade and other international disputes, war, and terrorism, including the military conflict between Russia and Ukraine.
• Operations may be impacted by natural disasters, which may become more frequent or severe as a result of climate change.
• Dependence on the acceptance of teledentistry and a demand for correcting tooth alignment.
• Adverse changes in, or interpretations of, laws, rules, and regulations governing remote healthcare and the practice of dentistry could have a material adverse effect on the business.
• Future sales of the Platform may depend on customers' ability to obtain reimbursement from third-party payors, such as insurance carriers.
• Business model depends on being able to reach consumers to raise brand awareness and encourage downloading the smartphone application, which may not prove successful or may become less effective or more costly.
• Business disruptions, whether internal or at key suppliers, could seriously harm financial condition.
• Success depends on key executive personnel, vendors, and relationships with key dental professionals and organizations.
• Changes in internet regulations could adversely affect the business.
• Disruptions at the FDA, other agencies, or notified bodies caused by funding shortages or global health concerns could hinder their ability to review and approve products.
• Misuse or off-label use of the Platform may harm reputation, result in product liability suits, or lead to costly investigations, fines, or sanctions by regulatory bodies.
• Business will expose the company to potential liability for the quality and safety of products and services, advertising, and sales practices.
• Increased focus on current and anticipated environmental, social, and governance (ESG) laws and scrutiny of ESG policies and practices may materially increase costs, expose to liability, and adversely impact reputation.
• Subject to consumer protection laws that regulate marketing practices and prohibit unfair or deceptive acts or practices.
• Subject to a number of risks related to credit card and debit card payments.
• Risks related to future international sales, including the need to obtain necessary foreign regulatory clearance or approvals.
• If the company infringes or violates the patents or proprietary rights of other parties or is subject to an intellectual property infringement or misappropriation claim, the ability to grow the business may be severely limited.
• Failure to secure trademark registrations could adversely affect the ability to market products and operate the business.
• May be subject to claims that employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and patent protection could be reduced or eliminated in case of non-compliance.
• Patent terms may be inadequate to protect the competitive position on product candidates for an adequate amount of time.
• Changes in, or interpretations of, accounting rules and regulations could result in unfavorable accounting charges.
• Effective tax rate may vary significantly from period to period due to global economic environment, changes in legal structure, tax laws, and other factors.

Future Outlook

The company anticipates continued significant operating losses as it develops the ZSmile Platform and expects to spend approximately $1 million over the next 12 months on software and hardware development, regulatory approvals, and IP protection. Future success depends on market acceptance of its products, ability to raise additional capital, and successful navigation of competitive and regulatory landscapes. The company aims for its AI-based image analysis to eventually approach the accuracy of intraoral scans, potentially replacing them for certain cases and dramatically increasing efficiency in the dental industry.

Management Comments

• "We have reimagined the way people can correct their smile. We plan to disrupt the aligner market by offering millions of people a revolutionary alternative."
• "We believe that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions."
• "We believe that recent rapid advancements in technology have made traditional aligner solutions no longer the most effective treatment option for smile correction."
• "We expect continued operating losses and cannot be certain of our future profitability."
• "Our management team lacks U.S. public company experience and is generally unfamiliar with the requirements of the U.S. securities laws and U.S. Generally Accepted Accounting Principles (GAAP), which could impair our ability to comply with legal and regulatory requirements."
• "We are evaluating various financing strategies to obtain sufficient additional liquidity to meet our operating and capital requirements for the next twelve months following the date of this Annual Report."
• "The Company is also enhancing corporate oversight over process level controls and structures to ensure appropriate assignment of authority."

Industry Context

StockSavvy.ai notes that Dror Ortho-Design is entering a rapidly growing clear aligners market, projected to reach $56.8 billion by 2033. Its focus on a single, nighttime-use smart aligner with AI-driven diagnostics and 3D printing aims to differentiate it from established players like Align Technologies (Invisalign), Dentsply Sirona (Byte), 3M Clarity Aligners, and Straumann Group, which primarily use multi-aligner thermoforming processes. The strategy to target general dentists, in addition to orthodontists, aligns with a broader industry trend of expanding orthodontic care delivery beyond specialists, potentially tapping into a significantly larger practitioner base.

Comparison to Industry Standards

• Dror Ortho-Design's ZSmile Platform, with its single smart aligner and pulsating air technology, contrasts with industry leader Align Technology's Invisalign, which typically requires a series of 20-30 plastic aligners worn all day.
• The company's claim of less pain and no lifestyle changes with ZSmile aims to address common patient complaints associated with traditional clear aligners and metal braces, potentially offering a competitive advantage over solutions from Dentsply Sirona (Byte) and 3M Clarity Aligners.
• The use of 3D printing for the actual aligners, rather than just models, is a significant technological advancement that Dror Ortho-Design believes is cost-effective due to its single-aligner approach, unlike the financially prohibitive nature for traditional multi-aligner systems.
• Clinical trials for the first-generation Aerodentis System demonstrated effectiveness consistent with Invisalign, suggesting ZSmile, as an improvement, could offer comparable clinical outcomes with a more convenient patient experience.
• The company's strategy to enable general dentists to provide orthodontic treatment with ZSmile expands its market reach significantly, contrasting with traditional models that heavily rely on orthodontists, similar to how some direct-to-consumer aligner companies have broadened access.

Corporate Governance

Legal Proceedings

• As of the filing date, the company is not a party to any material litigation nor is it aware of any threatened or pending litigation.
• No proceedings involve any directors, officers, affiliates, or stockholders as an adverse party or with a material interest adverse to the company's interest.

Related Party Transactions

• Yehuda Englander, a director, receives a monthly cash fee of $2,500 + VAT for financial and strategic consulting services, and was granted options to purchase 9,597,675 shares of Common Stock.
• Chaim Ravad, a director, received a cash fee of $5,000 each month for services as a board member, totaling $55,000, with the agreement terminating upon reaching this amount.
• Oriole Avenue Inc., an entity owned by Yaacov Bodner (a stockholder), entered into a consulting agreement for shareholder, investor relations, and general consultancy services, receiving $145,000 in cash payments and warrants to purchase 10,454,500 shares of Common Stock.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity or convertible debt financings, as well as potential volatility and limited liquidity of the common stock on the OTC Pink Market. The going concern warning indicates a high risk of losing all or a substantial portion of their investment.
• **Employees:** The company's ability to continue as a going concern directly impacts job security. The lack of a CFO and limited accounting personnel could affect operational stability and compliance.
• **Customers (future):** The successful commercialization of the ZSmile Platform, following FDA clearance, offers a new, potentially less intrusive and painful orthodontic treatment option. However, market acceptance and reimbursement availability are critical for widespread adoption.
• **Suppliers/Vendors:** The company's financial instability and need for capital raise could pose risks to timely payments and ongoing business relationships, especially for outsourced R&D partners like Aran Research Development Prototypes Ltd.
• **Creditors:** Bridge loan investors face the risk of the company's inability to repay debt if sufficient capital is not raised or a public offering does not materialize, although debentures convert to equity in a public offering.

Next Steps

• Spend approximately $1 million over the next 12 months on software and hardware development, regulatory approvals, and IP protection for the ZSmile Platform.
• Actively recruit and hire a Chief Financial Officer with public company experience and expertise in U.S. GAAP and SEC reporting to remediate internal control weaknesses.
• Engage internal control consultants to perform a financial reporting risk assessment and assist in designing a system of internal controls.
• Prepare written documentation of internal control policies and procedures across key business processes.
• Strengthen corporate governance.
• Monitor and assess the costs and benefits of additional staffing to fully remediate material weaknesses in internal controls.
• Evaluate various financing strategies to obtain sufficient additional liquidity, including debt and equity offerings.
• Apply to have common stock listed for trading on The Nasdaq Stock Market, assuming all necessary initial listing requirements are satisfied.

Key Dates

Recommendation

Dror Ortho-Design presents an extremely high-risk investment. Despite securing FDA clearance for its ZSmile Platform, the company is a development-stage entity with no revenues, significant and recurring net losses ($2.5M in 2025), a critical working capital deficit ($2.7M), and an accumulated deficit of $22 million. The independent auditor's 'substantial doubt' about its ability to continue as a going concern, coupled with identified material weaknesses in internal financial controls and a management team lacking U.S. public company experience, signals severe operational and financial instability. While the market opportunity is large, the company's current financial state and the need for substantial, uncertain future capital raises make it highly speculative. The stock's trading on the OTC Pink Market and penny stock rules further exacerbate liquidity and price volatility risks. Seasoned investors would view the fundamental financial health as severely compromised, outweighing any potential upside from product development.

Keywords

Orthodontics, Dental Devices, Clear Aligners, ZSmile, Aerodentis, FDA Clearance, Medical Device, AI Platform, Teledentistry, Dental Technology, Smile Correction, Pulsating Air, 3D Printing, Healthcare Regulation, Startup, Development Stage, Going Concern, SEC Filing, 10-K, Israel Operations